Parkinson's biomarker hunt: small study tests Leukine's effects
NCT ID NCT05677633
First seen Nov 05, 2025 · Last updated May 18, 2026 · Updated 28 times
Summary
This early-phase study looked at whether the drug Leukine (sargramostim) can help identify biological markers (biomarkers) in people with Parkinson's disease. Eleven participants received the drug for 48 weeks, and researchers monitored safety, immune cell changes, and movement symptoms. The main goal was to validate biomarkers, not to treat the disease directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE AND PARKINSONISM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.